Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T; Vytorin Extension Study Group. Ose L, et al. Among authors: tribble d. Int J Clin Pract. 2007 Sep;61(9):1469-80. doi: 10.1111/j.1742-1241.2007.01402.x. Epub 2007 Jul 26. Int J Clin Pract. 2007. PMID: 17655686 Clinical Trial.
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y. Feldman T, et al. Among authors: tribble d. Clin Ther. 2006 Jun;28(6):849-59. doi: 10.1016/j.clinthera.2006.06.001. Clin Ther. 2006. PMID: 16860168
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR; Ezetimibe Study Group. Bays HE, et al. Clin Ther. 2004 Nov;26(11):1758-73. doi: 10.1016/j.clinthera.2004.11.016. Clin Ther. 2004. PMID: 15639688 Clinical Trial.
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Dansky HM, Bloomfield D, Gibbons P, Liu S, Sisk CM, Tribble D, McKenney JM, Littlejohn TW 3rd, Mitchel Y. Dansky HM, et al. Among authors: tribble d. Am Heart J. 2011 Oct;162(4):708-16. doi: 10.1016/j.ahj.2011.07.010. Epub 2011 Sep 1. Am Heart J. 2011. PMID: 21982664 Clinical Trial.
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC. Bloomfield D, et al. Among authors: tribble d. Am Heart J. 2009 Feb;157(2):352-360.e2. doi: 10.1016/j.ahj.2008.09.022. Epub 2008 Dec 20. Am Heart J. 2009. PMID: 19185645 Clinical Trial.
360 results